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INTRODUCTION
In 2017, there were approximately 5200 patients waiting 
to receive a kidney transplant in the United Kingdom.1 
Because the number of patients waiting to receive a trans-
plant far outstrips the supply of organs from deceased 
donors, many countries have put in place allocation systems 
that make the criteria for prioritizing potential recipients 
transparent and explicit. In the United Kingdom, a match-
ing system between recipients and deceased donors has 
been in place since 1972.2 The approach to kidney alloca-
tion in the United Kingdom is subject to continuous audit 
and review, and over the decades, the national scheme has 
undergone a number of revisions to address and balance 
considerations of both improving transplant outcomes and 
promoting equity in access to transplantation.3,4
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Background. The number of patients waiting to receive a kidney transplant outstrips the supply of donor organs. We sought 
to quantify trade-offs associated with different approaches to deceased donor kidney allocation in terms of quality-adjusted life 
years (QALYs), costs, and access to transplantation. Methods. An individual patient simulation model was developed to com-
pare 5 different approaches to kidney allocation, including the 2006 UK National Kidney Allocation Scheme (NKAS) and a QALY 
maximization approach designed to maximize health gains from a limited supply of donor organs. We used various sources of 
patient-level data to develop multivariable regression models to predict survival, health state utilities, and costs. We simulated the 
allocation of kidneys from 2200 deceased donors to a waiting list of 5500 patients and produced estimates of total lifetime costs 
and QALYs for each allocation scheme. Results. Among patients who received a transplant, the QALY maximization approach 
generated 48 045 QALYs and cost £681 million, while the 2006 NKAS generated 44 040 QALYs and cost £625 million. When 
also taking into consideration outcomes for patients who were not prioritized to receive a transplant, the 2006 NKAS produced 
higher total QALYs and costs and an incremental cost-effectiveness ratio of £110 741/QALY compared with the QALY maximiza-
tion approach. Conclusions. Compared with the 2006 NKAS, a QALY maximization approach makes more efficient use of 
deceased donor kidneys but reduces access to transplantation for older patients and results in greater inequity in the distribution 
of health gains between patients who receive a transplant and patients who remain on the waiting list.
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Simulation modeling is a practical tool that can be used 
to evaluate or prospectively test the impact of potential 
changes to kidney allocation schemes.5–7 As part of the 
Access to Transplantation and Transplant Outcomes 
Measure (ATTOM) study, we conducted a simulation 
exercise to explore and compare alternative approaches to 
allocating kidneys from deceased donors in the UK con-
text. We approached the development of the simulation 
model with 3 key objectives in mind:
 1. to simulate different approaches to kidney allocation that 
reflect varying degrees of emphasis on the competing objec-
tives of efficiency and equity;
 2. to report outcomes for each kidney allocation scheme in 
terms of both quality-adjusted life years (QALYs) and 
costs; and
 3. to maximize use of information on individual patient and 
donor characteristics to inform the allocation process and 
account for between-patient variability in the estimation of 
outcomes.
Kidney Allocation Concepts of Interest
The last major revision to the UK kidney allocation 
scheme took place in 2006.4 In this simulation exercise, we 
compared the 2006 National Kidney Allocation Scheme 
(NKAS) to several alternative approaches, with a particu-
lar interest in exploring the feasibility of designing an allo-
cation scheme that maximizes health gains, expressed in 
terms of QALYs, among transplant recipients from a fixed 
supply of donor kidneys. The design of a QALY maximi-
zation allocation scheme was predicated on the following 
assumptions:
 1. For patients awaiting a transplant, there is a treatment 
alternative, namely dialysis.
 2. Not all donor kidneys will result in equally good survival 
outcomes.
 3. Not all potential recipients will derive the same survival 
benefit from a given donor kidney.
In the QALY maximization scheme, for each donor kid-
ney that becomes available, the simulation model estimates 
expected QALYs following transplant for each patient on 
the waiting list given the characteristics of both the patient 
and the donor kidney to be allocated. Next, the simulation 
model estimates expected QALYs for each patient on the 
waiting list if the patient were to remain on dialysis. After 
calculating the difference between expected QALYs follow-
ing transplant and expected QALYs on dialysis, each kidney 
is allocated to the patient who is expected to gain the most 
as a result of receiving the transplant. Over the population 
of transplant recipients, this approach to allocation should 
yield the maximum total QALY gains for a fixed number 
of donor kidneys. This QALY maximization scheme is con-
ceptually similar to the Life Years from Transplant calcula-
tion previously described by Wolfe et al,8 but in the current 
simulation exercise, we used UK data sources and adopted 
a different method to extrapolate survival using flexible 
parametric survival analysis to calculate QALYs.
A new kidney allocation scheme based on the concept of 
longevity matching was introduced in the United States in 
2014. Under this concept, donor kidneys are risk stratified 
using a scoring system to identify which kidneys are asso-
ciated with better posttransplant survival. Similarly, poten-
tial recipients on the waiting list are risk stratified based on 
estimates of their expected posttransplant survival (EPTS) 
score. The allocation policy then prioritizes candidates in 
the top 20th percentile of EPTS scores to receive kidneys 
from the top 20% of donor kidneys.9 The cost implications 
of this new allocation policy in the United States have been 
estimated.10 To test the concept of longevity matching in the 
UK context, we used a UK-specific kidney donor risk index11 
and developed a multivariable parametric model to estimate 
mean posttransplant survival for potential recipients based 
on an analysis of historical UK Transplant Registry data.12 A 
key difference between our approach to estimating recipient 
posttransplant survival and the EPTS score used in the US 
kidney allocation scheme is that our survival predictions also 
take into account 2 donor characteristics: age and history 
of hypertension. Thus, in our simulation exercise, recipient 
posttransplant survival estimates for both the QALY maxi-
mization and longevity matching allocation schemes are 
recalculated for each potential donor–recipient combination.
In addition to exploring the concepts of QALY maximi-
zation and longevity matching, we included 2 other alloca-
tion concepts in our simulation exercise that were intended 
to reflect greater emphasis on the principle of equity in 
access to transplant: random allocation and allocation 
based on waiting time. Table 1 provides an overview of all 
5 allocation concepts explored in our simulation exercise.
MATERIALS AND METHODS
Characteristics of Waiting List Patients and Donor 
Kidneys
To simulate the composition of the transplant waiting 
list, we obtained data on 1948 prevalent listed patients 
who were recruited into the ATTOM study between 
November 2011 and September 2013.13 Of these patients, 
513 had received a previous transplant. In the absence of 
predictive survival models that would allow us to account 
for prior transplants, we excluded these patients from the 
simulation exercise leaving a sample of 1435 patients, 
whose characteristics were replicated to make up a total 
waiting list of 5500 patients, which reflected the size of the 
waiting list at the time the simulation model was designed 
(Table  2). During the simulation exercise, each time a 
patient received a transplant, a replacement was added to 
the waiting list to keep it constant at 5500 patients. For the 
donor data set, we obtained characteristics of 2200 donors 
(4400 kidneys) from NHS Blood and Transplant based on 
a representative historical cohort reflecting the time period 
between January 2010 and December 2011 (Table 3).
Characteristics of individual patients and donors were 
assigned at the point of entry into the model so that these 
characteristics could be used throughout the simulation to 
inform the allocation process as well as to estimate sur-
vival, costs, and health state utilities. Most patient char-
acteristics, including comorbidities, were kept constant 
throughout the simulation, but 3 characteristics were 
updated as simulation time progressed; waiting time and 
time on dialysis were incremented on a daily basis, while 
patient age was incremented annually.
Model Structure and Assumptions
The simulation model was constructed using the soft-
ware package SIMUL8 2015 Professional version (SIMUL8 
Corporation, Boston, MA). At the start of the simulation, 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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prevalent waiting list patients are loaded and held in a queue, 
while donor kidneys are assumed to arrive at a fixed rate 
equivalent to 1200 deceased donors per year (Figure 1). The 
allocation process is triggered by the arrival of each donor 
kidney. Using Visual Logic, SIMUL8’s internal programming 
language, we are able to loop through patients on the waiting 
list to evaluate blood group and tissue compatibility for each 
potential donor–recipient combination and perform the nec-
essary calculations and scoring algorithms relevant to each 
allocation scheme of interest. In the model, we allowed for 
the possibility that no appropriate match is identified for a 
kidney from a donor with a rare blood or tissue type. This is 
unlikely to happen in practice but could occur in a small pro-
portion of cases in our simulation because the composition 
of the waiting list was based on a limited sample of patients 
who were recruited into the ATTOM study. In the current 
UK allocation scheme, tissue matching between the donor 
and recipient is determined on the basis of HLA; patients 
are separated into 1 of 4 possible HLA mismatch levels from 
level 1 (000-mismatched) to level 4 (poorly matched). In cur-
rent practice, patients with a level 4 HLA mismatch are not 
eligible to receive the donor kidney through the national allo-
cation scheme.4 In order to maintain comparability between 
allocation schemes, we applied the same minimum criteria 
for blood group and HLA matching to all allocation schemes 
in the simulation exercise.
Once a match has been identified, the recipient and 
donor kidneys are assembled into a single entity to simu-
late the transplantation event and moved to the next step 
in the simulation process to determine posttransplant 
survival and to estimate lifetime QALYs and costs. The 
model assumes that only 2 events are possible following 
transplantation: graft failure, in which the transplanted 
kidney stops working, or patient death. These events are 
modeled as competing risks in which we randomly sam-
ple from the survival curve for each event and move the 
patient to the event with the earliest sampled time.14 If a 
patient experiences graft failure, we have assumed that the 
patient returns to dialysis and faces the same mortality risk 
as a patient who has been on the waiting list and receiv-
ing dialysis for >3 years. However, if the sampled value 
for time to death following graft failure is longer than the 
time the patient would have survived based on the pre-
viously sampled value to determine initial posttransplant 
outcomes, we replaced it with the lower value. We did not 
attempt to model repeat transplants in the simulation.
The model was built by developing separate sections of 
Visual Logic code for each step in the allocation process so 
that, for example, the same procedure to evaluate blood 
group compatibility could be called at any point in the sim-
ulation for any of the 5 allocation schemes. Internal spread-
sheets were used extensively to perform interim calculations 
at the patient level, which also facilitated model checks and 
step-by-step verification of the simulation process.
Estimating Life Years, QALYs, and Costs
Survival Models
There are 3 survival models underpinning time-to-event 
calculations to estimate posttransplant patient survival, 
posttransplant graft failure, and waiting list survival at 
TABLE 1.
Description of the 5 kidney allocation schemes included in the simulation exercise
Allocation concept Description of allocation criteria considered in each scheme
Random Blood group compatibility and HLA match
Priority for HLA mismatch level 1 (000)
Taking the above criteria into account, allocate the kidney randomly
Waiting time Blood group compatibility and HLA match
Priority for HLA mismatch level 1 (000)
Taking the above criteria into account, allocate the kidney to the patient with the longest waiting time
2006 NKAS4 Priority for HLA mismatch level 1 (000), taking into account whether or not patients are highly sensitized or HLA-DR homozygous
Within tiers, prioritize patients according to a points-based system based on
 waiting time
 HLA match and age combined
 donor–recipient age difference
 location of patient relative to donor
 HLA-DR homozygosity
 HLA-B homozygosity
 blood group match
Longevity matching For each donor kidney, estimate expected posttransplant survival for each patient on the waiting list
If the donor kidney has a UKKDRI score in the top 20%, then 20% of patients with the longest expected posttransplant 
survival are prioritized to receive the kidney
Taking the above criteria into account, allocate the kidney according to the 2006 NKAS
QALY maximization Blood group compatibility and HLA match
Priority for HLA mismatch level 1 (000)
For each donor kidney, estimate expected posttransplant QALYs for each patient and expected QALYs if each patient were to 
remain on the waiting list (on dialysis)
Taking the above criteria into account, allocate the kidney to the patient with the biggest expected QALY gain from transplant
HLA, human leukocyte antigen; NKAS, National Kidney Allocation Scheme; QALY, quality-adjusted life y; UKKDRI, UK-specific kidney donor risk index.
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various points in the simulation. Each of these models was 
developed based on analysis of historical UK Transplant 
Registry data. Data on dialysis start dates were addition-
ally obtained through linkage to the UK Renal Registry to 
inform the waiting list survival model. Models were fitted 
using flexible parametric survival analysis to facilitate:15
 1. extrapolation of survival curves to allow calculation of 
mean survival in years; and
 2. inclusion of relevant patient and donor characteristics 
as covariates to capture variability in our predictions of 
survival and by extension in our estimates of costs and 
QALYs.
A more detailed description of the method used to fit 
the posttransplant patient survival model is described else-
where.12 A summary of the patient and donor character-
istics that were included as covariates in each of the final 
models is provided in Table S1 (SDC, http://links.lww.com/
TP/B788). When the survival models were used as part of 
the allocation process to match recipients and donor kid-
neys (longevity matching and QALY maximization), they 
were applied deterministically to produce mean survival 
estimates. When the survival models were used to inform 
competing risks following transplantation to estimate life-
time QALYs and costs, we allowed for stochastic variation.
Health State Utility Estimates
Health state utility estimates for transplant recipient and 
patients on the waiting list were captured in the ATTOM 
study using the EQ-5D-5L questionnaire. We developed 
multivariable regression models to identify patient char-
acteristics that led to variations in utility scores to inform 
quality adjustment of survival estimates in the simulation 
model (see Table S2 (SDC, http://links.lww.com/TP/B788) 
for a list of characteristics included in the final models).16
Costs
The costs of maintenance dialysis and transplant sur-
gery were estimated in the simulation by applying fixed 
national tariffs.17 We estimated annual hospital costs using 
2-part regression models that were developed by analyz-
ing patient-level data from linkage of the Hospital Episode 
Statistics data set to UK Renal Registry data.18 Hospital 
costs were captured by treatment modality (dialysis ver-
sus transplantation) and by hospital setting (inpatient ver-
sus outpatient) and regression models included a number 
of patient characteristics as covariates (Table S3A and 
B, SDC, http://links.lww.com/TP/B788). For transplant 
recipients, the annual cost of maintenance immunosup-
pression assumed that patients received a combination of 
corticosteroids, a calcineurin inhibitor (cyclosporine or 
tacrolimus), and an antiproliferative agent (mycopheno-
late mofetil or azathioprine).19
Running the Simulation
For each allocation scheme, we performed 3 runs using a 
separate random number stream for each run. A single run 
ends when all 4400 donor kidneys have been allocated or 
TABLE 2.
Characteristics of the recipient cohort (n = 5500) used in 
the simulation model
n (%)
Age, y  
 18–29 369 (6.7)
 30–39 708 (12.9)
 40–49 1245 (22.6)
 50–59 1576 (28.7)
 ≥60 1602 (29.1)
Sex
 Female 2320 (42.2)
Ethnicity
 White 4017 (73.0)
 Asian 727 (13.2)
 Black 626 (11.2)
 Other 140 (2.6)
Blood group
 O 3135 (57.0)
 A 1590 (28.9)
 B 684 (12.4)
 AB 91 (1.7)
Highly sensitized 468 (8.5)
Primary renal diagnosis
 Diabetes 826 (15.0)
 Polycystic kidney disease 82 (1.5)
Comorbidities
 Ischemic heart disease 475 (8.6)
 Congestive heart failure 178 (3.2)
 Peripheral vascular disease 199 (3.6)
 Cerebrovascular disease 293 (5.3)
 Respiratory disease 447 (8.1)
 Liver disease 74 (1.4)
 Malignancy 262 (4.8)
 Mental illness 403 (7.3)
Smoker 730 (13.3)
Y on dialysis at time of listing
 Predialysis 2413 (43.9)
 <1 y 1490 (27.1)
 1–3 y 879 (16.0)
 >3 y 263 (4.8)
 Missing 455 (8.3)
TABLE 3.
Characteristics of the donor cohort (n = 2200) used in the 
simulation model
n (%)
Age, y
 <30 394 (17.9)
 30–39 283 (12.9)
 40–49 503 (22.9)
 50–59 548 (24.9)
 ≥60 472 (21.5)
Blood group
 O 1024 (46.5)
 A 892 (40.5)
 B 197 (9.0)
 AB 87 (4.0)
History of hypertension 499 (22.7)
UK kidney donor risk index  
 High risk (≥1.35) 582 (26.5)
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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removed from further consideration if no match has been 
identified. The proportion of donor kidneys for which no 
match was identified was approximately 1% across all 
simulation runs, and therefore, the number of patients who 
received a transplant was similar across allocation schemes.
Although we are primarily interested in comparing total 
costs and QALYs across all transplant recipients resulting 
from the different allocation schemes, it is also important 
to consider the outcomes of those patients who did not 
receive a transplant within the time frame of the simula-
tion. For these patients, we made a simplifying assumption 
that they face a mortality risk equivalent to remaining on 
the waiting list until death and used this as the basis for 
projecting their lifetime costs and QALYs at the end of the 
simulation. QALYs and costs were both discounted at an 
annual rate of 3.5%.20
For each allocation scheme, we report the characteris-
tics of patients who received a transplant, the distribution 
of life years and QALYs for transplant recipients by age 
group, and the total discounted costs and QALYs for 
patients who received a transplant, for patients who 
remained on the waiting list and for the overall cohort.
RESULTS
Access to Transplantation
To understand the impact of the different allocation 
schemes on access to transplantation, Table 4 reports the 
age, sex, and diabetes status of patients who received a 
transplant. Moving along the equity–efficiency spectrum 
from random allocation toward allocation based on QALY 
maximization, there is a notable decrease in the average age 
of transplant recipients. Under random allocation, which 
preserves the composition of the original waiting list at the 
start of the simulation, 31% of transplant recipients were 
aged ≥60 years; under the QALY maximization approach, 
FIGURE 1. Structure of the simulation model.
TABLE 4.
Summary of characteristics of patients who received a transplant under each allocation scheme
Random Waiting time 2006 NKAS Longevity matching QALY maximization
Mean age (SD), y 51.4 (12.8) 52.5 (12.3) 46.6 (12.5) 46.3 (12.6) 41.8 (10.7)
Age group, y
 18–29 7% 5% 10% 10% 15%
 30–39 12% 11% 19% 20% 27%
 40–49 22% 21% 28% 29% 36%
 50–59 28% 30% 25% 23% 18%
 ≥60 31% 33% 18% 18% 4%
Female 42% 43% 44% 44% 50%
Diabetes 15% 15% 14% 14% 11%
NKAS, National Kidney Allocation Scheme; QALY, quality-adjusted life y; SD, standard deviation.
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this proportion fell to just 4%. Allocation schemes that 
emphasized greater efficiency also resulted in a higher pro-
portion of female transplant recipients and a lower pro-
portion of transplant recipients with diabetes.
Distribution of Life Years and QALYs
Table 5 shows mean survival (life y) and mean QALYs 
for each allocation scheme. The QALY maximization 
scheme resulted in the highest mean life years and QALYs 
for each transplant recipient (23.6 life y, 19.3 QALYs) but 
correspondingly the lowest mean life years and QALYs for 
patients who were not prioritized to receive a transplant 
(6.5 life y, 5.1 QALYs). The waiting time allocation scheme 
resulted in the lowest mean life years and QALYs for each 
transplant recipient (17.1 life y, 13.9 QALYs) and also 
resulted in the smallest difference in survival for those who 
received a transplant compared with those who did not.
Although the QALY maximization scheme resulted in 
the lowest proportion of patients aged ≥60 years receiv-
ing a transplant (4%), those who did receive a transplant 
survived longer on average than patients aged ≥60 years 
under any of the other allocation schemes. This is because 
the QALY maximization scheme is selecting patients who 
are expected to live long enough to derive the biggest 
survival benefit from each donor kidney compared with 
remaining on dialysis.
Cost-effectiveness Results
The motivation behind the QALY maximization 
approach is to make the most efficient use of a scarce 
supply of kidneys. Table 6 shows total QALYs and costs 
for the entire cohort of patients in the simulation. For 
patients who received a transplant, the QALY maximiza-
tion approach generated the highest total QALYs (48 045) 
and also led to the highest costs (£681 million). However, 
Table 6 also shows that patients who were not prioritized 
to receive a transplant and who remained on the waiting 
list had worse health outcomes and generated fewer total 
QALYs (20 504) compared with other allocation schemes.
Taking into account total costs and QALYs for both 
transplant recipients and patients who remained on the 
waiting list, longevity matching produced the fewest 
QALYs (65 665) and the lowest costs (£1473 million), 
while the 2006 NKAS produced the most QALYs (70 569) 
TABLE 5.
Average undiscounted life y and QALYs per patient for each allocation scheme
 
Random allocation Waiting time 2006 NKAS Longevity matching QALY maximizing
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Life y           
 Transplant recipients (by age group)           
  18–29 27.2 (24.7-29.7) 27.2 (24.0-30.3) 32.8 (30.3-35.3) 31.5 (29.3-33.7) 29.2 (27.3-31.2)
  30–39 26.5 (24.6-28.4) 25.4 (23.5-27.3) 29.2 (27.7-30.8) 30.1 (28.6-31.7) 27.5 (26.2-28.8)
  40–49 23.4 (22.3-24.6) 22.2 (21.0-23.3) 23.4 (22.4-24.5) 22.6 (21.6-23.6) 23.4 (22.5-24.4)
  50–59 15.2 (14.5-15.9) 15.0 (14.3-15.7) 14.5 (13.8-15.2) 14.5 (13.7-15.2) 15.6 (14.7-16.6)
  >60 11.2 (10.7-11.6) 11.4 (11.0-11.9) 10.7 (10.2-11.3) 11.0 (10.4-11.6) 13.2 (11.5-14.8)
 Transplant recipients (all) 18.0 (17.5-18.5) 17.1 (16.7-17.6) 21.1 (20.5-21.7) 21.2 (20.7-21.8) 23.6 (23.0-24,2)
 No transplant (all) 8.9 (8.8-9.1) 9.0 (8.9-9.1) 9.0 (8.9-9.1) 6.8 (6.7-6.9) 6.5 (6.4-6.6)
QALYs           
 Transplant recipients (by age group)           
  18–29 22.4 (20.4-24.5) 22.4 (19.8-24.9) 27.1 (25.0-29.2) 26.0 (24.1-27.8) 24.1 (22.5-25.7)
  30–39 21.4 (19.9-22.9) 20.6 (19.1-22.2) 23.8 (22.5-25.1) 24.5 (23.2-25.8) 22.4 (21.3-23.5)
  40–49 18.9 (18.0-19.9) 17.9 (17.0-18.8) 18.9 (18.0-19.8) 18.3 (17.5-19.1) 19.1 (18.3-19.9)
  50–59 12.3 (11.7-12.9) 12.1 (11.6-12.7) 11.7 (11.1-12.3) 11.7 (11.1-12.3) 12.7 (12.0-13.5)
  >60 9.0 (8.7-9.4) 9.2 (8.8-9.6) 8.7 (8.2-9.1) 8.9 (8.4-9.4) 10.7 (9.3-12.0)
 Transplant recipients (all) 14.6 (14.2-15.0) 13.9 (13.5-14.2) 17.1 (16.6-17.6) 17.2 (16.8-17.7) 19.3 (18.8-19.8)
 No transplant (all) 6.9 (6.8-7.0) 6.9 (6.9-7.0) 7.0 (6.9-7.1) 5.2 (5.1-5.3) 5.1 (5.0-5.1)
CI, confidence interval; NKAS, National Kidney Allocation Scheme; QALY, quality-adjusted life y.
TABLE 6.
Cost-effectiveness results for transplant recipients, patients who did not receive a transplant and all patients combined
Transplant recipients No transplant All patients
Absolute  
costs
Absolute 
QALYs
Absolute  
costs
Absolute 
QALYs
Absolute  
costs
Absolute 
QALYs
Incremental 
costs
Incremental 
QALYs ICER
Longevity matching £632 44 704 £841 20 961 £1473 65 665 – – –
QALY maximization £681 48 045 £818 20 504 £1499 68 549 £25 2884 £8751
Random £591 40 236 £1089 26 328 £1679 66 563 £181 −1986 Dominated
Waiting time £584 39 496 £1099 26 572 £1684 66 068 £185 −2481 Dominated
2006 NKAS £625 44 040 £1097 26 529 £1722 70 569 £224 2020 £110 741
ICER, incremental cost-effectiveness ratio; NKAS, National Kidney Allocation Scheme; QALY, quality-adjusted life y.
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and the highest costs (£1722 million). While the longevity 
matching and QALY maximization schemes both gener-
ated more QALYs for transplant recipients than the 2006 
NKAS, they generated far fewer QALYs for those patients 
who were assumed to remain on the waiting list. In incre-
mental cost-effectiveness analysis, random allocation and 
waiting time allocation were both dominated; that is to 
say, they were both less effective and more costly than at 
least one of the other allocation approaches. The com-
parison of the QALY maximization approach to longevity 
matching generated an incremental cost-effectiveness ratio 
(ICER) of £8751/QALY, while the comparison of the 2006 
NKAS to the QALY maximization approach generated an 
ICER of £110 741/QALY (Figure 2).
DISCUSSION
The allocation of deceased donor kidneys to patients 
who are awaiting a transplant is constrained not only by 
a limited supply of kidneys but also, like all resource allo-
cation decisions in health care, by a limited budget. The 
emphasis of the literature and the debate about kidney 
allocation has historically focused on donor organs as the 
only constraint and in particular on the trade-off between 
maximizing survival and ensuring equity in access to 
transplantation. In this research, we have explored a wider 
range of potential objectives in the design of a kidney allo-
cation scheme and used simulation modeling to quantify 
the magnitude of trade-offs associated with moving from 
one allocation approach to another. In particular, this is 
the first patient-level simulation exercise to consider the 
costs associated with different approaches to kidney allo-
cation in the United Kingdom and to report outcomes in 
terms of QALYs.
The motivation for the simulation exercise described 
in this article was not only to explore different allocation 
concepts from across the equity–efficiency spectrum but 
also to improve our ability to estimate variability in out-
comes resulting from different approaches to allocation 
using patient-level data. If alternative approaches to kid-
ney allocation result in different patients receiving trans-
plants, then an accurate comparison of the consequences 
of alternative allocation schemes depends on our ability 
to predict variability in outcomes dependent on individual 
patient characteristics. This simulation exercise relied on 
a number of rich sources of patient-level data including 
the ATTOM study, the UK Transplant Registry (held by 
NHS Blood and Transplant), Hospital Episode Statistics, 
and the UK Renal Registry to develop predictive regression 
models to estimate survival, health state utilities, and costs. 
These predictive models were used not only to estimate 
QALYs and costs for transplant recipients in all 5 alloca-
tion schemes but also as part of the criteria to inform the 
kidney allocation process for the longevity matching and 
QALY maximization schemes.
Our research demonstrates the richness of information 
that can be generated from a patient-level simulation, but 
we are cognizant that there are limitations to any modeling 
exercise. In particular, we made a number of assumptions 
with respect to the model structure, such as only consider-
ing first-time transplants and excluding pediatric patients 
as the latter group fell outside of the scope of the ATTOM 
study. The characteristics of the donors were based on a 
contemporaneous cohort with the waiting list patients in 
the ATTOM study, but we have not attempted to model 
the consequences of the different allocation schemes if the 
composition of either the donor pool or the waiting list 
were to change significantly over time. Another important 
simplifying assumption was that patients who were on the 
waiting list at the end of the simulation would not receive 
a transplant in the future. This assumption is unlikely to 
be met in practice. Survival on the waiting list is on aver-
age poorer than survival following transplant, so the likely 
effect of this assumption is that we have underestimated 
total QALYs for all allocation schemes. It is difficult to 
anticipate the net impact of this assumption on the cost-
effectiveness results. Different allocation criteria will result 
in different types of patients receiving transplants, and 
by corollary, the composition of patients who remain on 
the waiting list will also differ between schemes. Under 
the waiting time allocation scheme, patients who remain 
on the waiting list at the end of the simulation would in 
practice still have a reasonable prospect of receiving a 
future transplant as their likelihood of being prioritized 
for transplant increases with time. In contrast, under the 
QALY maximization scheme, patients who remain on the 
waiting list at the end of the simulation may be less likely 
FIGURE 2. Cost-effectiveness plane showing the relative positions of the 5 allocation schemes in terms of both total costs (vertical axis) 
and total QALYs (horizontal axis) for all patients. NKAS, National Kidney Allocation Scheme; QALY, quality-adjusted life y.
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to receive a future transplant if their expected QALY gains 
from transplant decrease over time relative to new patients 
joining the waiting list. Rather than attempt to apply dif-
ferent assumptions to each allocation scheme to project 
what proportion or which types of patients on the wait-
ing list are likely to receive a future transplant at the end 
of the simulation, we chose to implement a standardized 
assumption so as not to confound our ability to observe 
and compare the effect of the different allocation schemes 
themselves. Given the importance of this assumption on 
estimates of QALYs and costs for the total patient popu-
lation, future research should focus on testing alternative 
assumptions, for example, by exploring if a nonterminat-
ing model could achieve a steady-state outcome that can 
be compared across allocation schemes over a long enough 
period of time. As with all simulation exercises, the need 
to make simplifying assumptions may limit the generaliz-
ability of the results to the real-world context. With these 
caveats in mind, simulation modeling is still an important 
tool that can help increase our understanding of the poten-
tial consequences of different approaches to kidney alloca-
tion under the same set of conditions in comparison to 
each other.
Although we chose to report lifetime QALYs and costs 
as the main outcomes of interest, this simulation exer-
cise was not specifically designed with standard methods 
for cost-effectiveness modeling at the forefront of our 
approach.21 There were both technical and philosophi-
cal reasons that contributed to this decision. During 
development of the simulation model, primary empha-
sis was placed on the design, feasibility, and coding of 
the different allocation schemes. Each scheme requires 
the simulation model to loop through all patients on 
the waiting list to evaluate donor–recipient compat-
ibility. In the case of the QALY maximization and lon-
gevity matching schemes, survival predictions take into 
account both recipient and donor characteristics and 
therefore need to be recalculated for all 5500 patients 
on the waiting list each time a donor kidney enters the 
simulation. The computational burden of the allocation 
process itself led to long model running times even in 
the absence of introducing parameter uncertainty, and 
therefore, we were unable to perform full probabilistic 
sensitivity analysis. On a more philosophical note, kid-
ney allocation represents a particular resource alloca-
tion problem constrained not only by a finite healthcare 
budget but also by a limited supply of donor organs. 
Conventional cost-effectiveness methods focus on max-
imizing health gains,22 but in the case of kidney allo-
cation, it is clear from current policy that maximizing 
health gains is not the only objective. For this reason, we 
presented incremental cost-effectiveness results for the 5 
allocation schemes but refrained from evaluating ICERs 
with respect to a specific threshold value. The results 
of this simulation exercise cannot answer the question 
about what the objectives of a national kidney allocation 
scheme should be, but nonetheless provide insight into 
the magnitude of QALY and cost differences to inform 
the discussion about trade-offs associated with alterna-
tive allocation concepts from across the equity–efficiency 
spectrum.
The QALY maximization approach to kidney alloca-
tion was designed to maximize health gains from a limited 
supply of donor kidneys. This approach yielded the most 
QALYs for transplant recipients but also resulted in a nota-
ble decrease in access to transplantation for older patients. 
Although the QALY maximization approach made more 
efficient use of a limited number of kidneys, it resulted in 
greater inequity in terms of both access to transplantation 
and the distribution of QALYs between transplant recipi-
ents and patients who remained on the waiting list.
A different kind of trade-off was evident when we con-
sidered the costs associated with each of the approaches 
to kidney allocation. The 2006 NKAS resulted in a mod-
est increase in total QALYs across all patients compared 
with the QALY maximization approach but also incurred 
much higher total costs. If the 2006 NKAS is viewed as a 
compromise between equity and efficiency, then the results 
of this simulation provide an estimate of the additional 
cost to the National Health Service of maintaining greater 
equity in the allocation of deceased donor kidneys.
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